Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
about
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of InfectionCombinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal DiseaseWhat we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible EnterobacteriaceaePopulation pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
P2860
Q26998883-2B94A0D8-7637-4AAA-8FF7-314211E8AB8FQ34299064-98A264AB-B9B9-40E7-9CB7-E754F9336D3FQ34393008-8524E188-F2F2-424E-A9C4-404A2BBE96F2Q35004269-286594A9-17CA-465B-9158-DC86C89C56ECQ35385445-FFE59B7D-CF22-47E9-A559-E3F0D8CDCF06Q36438924-C74CC150-0ABC-4005-815D-C5B56953A492Q36730017-421862F1-49B6-4AAC-AFA9-203686945370Q37308807-B9B6483C-0963-4C4B-99C1-623F39C88ACCQ37335781-68C42B38-CAAE-4854-8EC7-0FFD545898FBQ37428654-1129960D-F226-437D-8FB9-4E3955E91F7CQ38664871-EB0889BC-C343-42E0-B30C-FDB97B068A5CQ38690748-48FDC7EA-1570-4CEF-B57B-EEF2FDC54FD3Q38718394-072592B8-B3A5-46C3-8D73-A50268097D6EQ38838763-A4059292-AFA4-4004-A7E4-B7A17211D0E1Q38891891-D37DB325-9AA5-40C9-B6D4-602F8B167FB3Q39001350-677316EE-8836-4EBE-8896-75210A828075Q39037981-82B88236-570B-444E-B8CA-D139A4F1E9D1Q39066154-35025691-611B-4CAD-A877-49D345ABBF28Q39120027-83F03354-D1DC-40E5-A1AA-512BF80721C6Q39516974-D8F819A1-A075-40E1-A8EB-E6ECD31E896FQ39683724-7A8FC14C-B6D2-42CF-98AB-6C022CDD9F4EQ39940279-4A637C73-A567-4809-8273-C2C520801995Q40401367-67D2AEDD-1321-41A8-89E3-1A2AED1D451CQ41040157-5D625F1A-00FB-4158-A783-F2F787250792Q41139120-8A26E310-6DC2-45BD-98AE-DC18AF12CB02Q42109987-8F96AB28-5896-48A4-816D-B9BFFC8C5DC4Q42237788-B2AE246B-7257-4B8F-9AC3-C99715495AD4Q43126004-20D9C9CA-AE27-4B69-A0D6-623A74793E11Q47923622-A337D10F-CEA7-415C-9B2E-305D86EA7BECQ47923627-D9860907-08E3-4E1C-9FA7-842C2A8AB6E5
P2860
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@en
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@nl
type
label
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@en
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@nl
prefLabel
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@en
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics-pharmacodynam ...... n an in vitro infection model.
@en
P2093
Alan Forrest
Anthony M Nicasio
Brian VanScoy
Catharine C Bulik
Judith N Steenbergen
Lawrence V Friedrich
Olanrewaju O Okusanya
Paul G Ambrose
Rodrigo E Mendes
Ronald N Jones
P2860
P304
P356
10.1128/AAC.02513-12
P407
P577
2013-04-29T00:00:00Z